A differential analysis of DSS to uncover drugs with higher activity in cancer cells compared to non-malignant HOSEs revealed increased DSSs of several kinase inhibitors, including IAP/SMAC mimetics (NVP-LCL161 and birinapant) and ERK/MEKi (trametinib, selumetinib, cobimetinib, ulisertinib, and binimertinib), among others (Figure 6E). Here, DIABLO is linked to cancer.